Month: February 2024

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2023. Financial ResultsFourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 Reiterated 2024 revenue guidance of $600 – $630 million Fourth quarter net income of $31.4 million, compared to $16.6 million in fourth quarter 2022 2023 net income of $106.1 million, compared to $101.4 million in 2022 Cash and investments of $425.4 million as...

47% Revenue Growth in B2 Cloud Storage, 25% Revenue Growth Overall in Q4 2023 SAN MATEO, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Backblaze, Inc. (Nasdaq: BLZE), a leading specialized storage cloud platform, today announced results for its fourth quarter and year ended December 31, 2023. “Backblaze capped off a strong finish to the year with our B2 Cloud Storage revenue growing 47% in Q4 and delivered adjusted EBITDA profitability for the first time as a public company,” said Gleb Budman, CEO of Backblaze. “We exited 2023 with accelerated revenue growth and dramatically improved profitability and cash usage metrics. I’m excited for the coming year as Backblaze continues to move up in the mid-market and help customers who are poorly served by legacy solutions to break free with our differentiated cloud services.” Fourth Quarter...

Subscription revenue growth accelerated while margins continued to expand sequentiallyTrupanion, Inc.Total Revenue by QuarterSEATTLE, Feb. 15, 2024 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, today announced financial results for the fourth quarter and full year ended December 31, 2023.   The financial results are preliminary and subject to completion of the Company’s audit as described below.    “I am pleased that Q4 showed continued improvement in our financial metrics,” said Darryl Rawlings, CEO and Chair of the Board. “The combination of accelerated subscription revenue growth, continued margin expansion and efficient acquisition spend drove another quarter of positive free cash flow.” Fourth Quarter 2023 Financial and Business HighlightsTotal revenue...

SAN FRANCISCO, Feb. 15, 2024 (GLOBE NEWSWIRE) — Opendoor Technologies Inc. (Nasdaq: OPEN), a leading e-commerce platform for residential real estate transactions, today reported financial results for its fourth quarter and year ended December 31, 2023. Opendoor’s fourth quarter and year-end 2023 financial results and management commentary can be accessed through the Company’s shareholder letter on the “Quarterly Reports” page of Opendoor’s investor relations website at https://investor.opendoor.com. “The past year was about focus, execution, and progress. Our fourth quarter results exceeded the high end of our prior guidance ranges, demonstrating our ability to deliver, despite ongoing uncertainty in the housing market. We increased our home acquisitions sequentially throughout the year, built a new book of inventory that is performing...

SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international) and refer to conference ID PCVXQ423. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the...

MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Tuesday, March 5, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://edge.media-server.com/mmc/p/p69edqps. Individuals interested in participating in the call via telephone may access the call by dialing +1-888-886-7786 and referencing Conference ID 91932269. The webcast will be archived on the company’s investor...

ATHENS, Greece, Feb. 15, 2024 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three and twelve-month periods ended December 31, 2023.   Fourth Quarter 2023 Highlights:Total net revenues of $15.9 million.Net income attributable to controlling shareholders, of $0.3 million or $0.13 earnings per share basic and diluted.Adjusted net income1 attributable to controlling shareholders, for the quarter of $1.9 million, or, $0.71 and $0.70 per share basic and diluted, respectively.Adjusted EBITDA1 was $6.6 million.An average of 12.2 vessels were owned and operated during the fourth quarter of 2023 earning an average time charter equivalent rate of $14,570 per day.As...

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 Recently established partnership with AbCellera to jointly discover, develop, and commercialize a portfolio of next generation precision ADCs Current cash runway into 2026 with $232.9 million in cash, cash equivalents and marketable securities as of December 31, 2023 WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.    “In 2023, we...

Increases Quarterly Dividend 11% to $0.61 per Share LOUISVILLE, Ky., Feb. 15, 2024 (GLOBE NEWSWIRE) — Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 and 52 weeks ended December 26, 2023. Financial Results Financial results for the 13 and 52 weeks ended December 26, 2023 and December 27, 2022 were as follows:                                         13 Weeks Ended   52 Weeks Ended    ($000’s)   December 26,2023   December 27,2022   % change   December 26,2023   December 27,2022   % change    Total revenue   $ 1,164,361   $ 1,009,529   15.3 % $ 4,631,672   $ 4,014,919   15.4 %  Income from operations     83,773     68,853   21.7 %   353,989     320,197   10.6 %  Net income     72,430     59,869   21.0 %   304,876     269,818   13.0 %  Diluted earnings per share   $ 1.08   $ 0.89   21.3 % $ 4.54   $ 3.97   14.3 %  Results...

SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent HighlightsRecognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022 Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter Granted new physician and hospital reimbursement for coronary IVL in the United States. Three newly created MS-DRGs specific to coronary IVL for hospital payment in the inpatient setting became effective...